Paul McKenzie
Paul McKenzie is the Chief Executive Officer of CSL Limited, an Australian global biotechnology company headquartered in Melbourne. Under his leadership, CSL has continued to grow, posting strong financial results and focusing on the development and distribution of life-saving medicines. McKenzie has emphasized the importance of vaccinations and public health initiatives, particularly in light of the challenges posed by vaccine skepticism in the United States. His commitment to advocating for vaccinations is crucial as CSL navigates the impact of declining vaccination rates on its flu vaccine unit, Seqirus.
Not in the pool (under ¢1).
Recent news mentions
Paul McKenzie was the chief executive of CSL who was recently retired.
Claudia Karvan to headline UniSuper International Women’s Day event at venue accused of exploiting women
Australia· 2026-02-11
Dr Paul McKenzie was retiring with immediate effect that day.
RFK policies wipe $10 billion wiped off biotech giant’s valueAustralia· 2026-02-11
Paul McKenzie, the CEO of CSL, referred to the increased uncertainty in the pharmaceutical industry.
CSL wird mit Vifor Pharma nicht glücklich
Switzerland· 2025-08-21
Paul McKenzie is the chief executive of CSL, discussing the impact of Trump's tariffs on the company's US exports.
How Trump tariffs and RFK loom large for Australian health and biopharmaceutical giantAustralia· 2025-08-19
CSL chief executive Paul McKenzie said the company is taking the opportunity to make significant changes that will continue to drive shareholder returns over the long run.
Trump-Zelensky meeting at White House over Russia-Ukraine war; economic reform roundtable to begin; Hamas accepts Arab-mediated ceasefire dealAustralia· 2025-08-18Paul McKenzie, CEO of JetBlue, expressed his impression of China's investment in health as beneficial for global health.
记者去哪儿：这个春天，跨国企业再赴“中国之约”--经济·科技--人民网
China· 2025-03-24
Paul McKenzie described CSL's half-year results as robust, with net profit rising year-on-year.
CSL hit by falling vaccination rates in Trump’s AmericaAustralia· 2025-02-11
Paul McKenzie described CSL's half-year results as robust, with net profit rising year-on-year.
CSL hit by falling vaccination rates in Trump’s AmericaAustralia· 2025-02-11